By: Conor Hale
Senseonics (NYSE: SENS) has launched its first clinical study of a transmitter-free version of its Eversense 365 continuous glucose monitor.
Conor Hale is a Senior Editor at FierceMedTech and FierceBiotech. He specializes in reporting on medical developments, healthcare technology, and innovations in medical equipment, with a keen focus on digital health and telehealth. Conor's work has been featured in Fierce Biotech, NewsBreak, Fierce Pharma, Drug Delivery Business News, Medical Design & Outsourcing, and MassDevice.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Conor Hale's coverage is heavily focused on medical technology, healthcare, FDA approvals, and biotechnology. His articles often cite data and press releases from the private sector. He frequently covers stories related to new product launches, regulatory issues in the healthcare industry, and advancements in medical technology.
To effectively reach out to Conor Hale regarding potential article ideas or pitches, consider offering exclusive access to experts who can provide insights into emerging trends in medical technology and healthcare. Additionally, sources with deep knowledge of FDA approval processes or those involved in innovative AI applications within the healthcare sector may be of interest to him.
As he does not have a specified geographic focus but covers global developments in the industry without regional limitations.
This information evolves through artificial intelligence and human feedback. Improve this profile .